旅游产业实力评价与广西旅游强省建设

本文构建了省域旅游产业实力传统评价指标体系和综合评价指标体系,并运用这两个指标体系分别对广西旅游产业实力及其在全国的排名进行了评价与分析。在综合分析内外部环境与条件的基础上,提出了广西旅游强省建设2006～2020年的目标体系．以及以“政府主导、区域合作、产业联动、资源整合、企业增效”为总体指导思想,加快广西旅游强省建设的对策。     

海峡两岸经济合作:创新与双赢——第二次海峡两岸经济发展论坛综述

2008年5月17～18日,由国际欧亚科学院中国科学中心发起,福建师范大学、厦门大学、福建省社会科学界联合会联合主办的第二次“海峡两岸经济发展论坛（福州）”在福州举行。来自大陆、台湾、香港的知名专家学者、企业界高层人士、120余人参加会议。专家们从两岸经济合作发展的新机遇、制度创新与创造双赢、两岸经济进一步合作的动力、基础与模式、两岸产业合作、建设海峡西岸经济区等方面,阐述了各自的思考、建议与依据。现将论坛的主要观点综述如下。     

跨国公司全球化与本土化的融合--理论、实证分析与中国的对策研究

全球化与本土化的日益融合,正在成为当代跨国公司生产经营活动的趋势。文章从全球化与本土化融合的理论依据入手,分析了全球化与本土化融合与培育竞争优势的关系,实证研究了摩托罗拉和海尔的全球化与本土化融合,最后,提出中国跨国公司应采取的对策。     

制造业与物流业联动发展的产业协调度研究--基于陕西省数据实证分析

运用复合系统模型,计算了陕西省制造业子系统与物流业子系统的有序度,以此为基础,测算得出陕西全省及按照省域细分的陕北、关中、陕南三个组成区块各子系统有序度和复合系统协调度,进而分析了陕西全省及三个组成区块协调度在研究时段的变化态势。结果显示：制造业子系统有序度贡献最大的序参量是增加值,陕北区块的增加值提升最快;物流业子系统有序度贡献最大的是投资额,关中区块的投资额保持领先。通过对陕西省及各区块产业协调度的研究分析发现,各区块内产业间协调度呈现上升趋势,但陕西全省协调程度呈现M型变化趋势,两业之间联动关系围绕着“协调-不协调-协调”过程循环。     

中国西部物流业与经济发展的互动分析--基于丝绸之路经济带的省域实证研究

文章基于物流业增加值、服务业增加值等西部省市的平衡面板数据,对中国西部区域物流业发展现状与区域经济的关系进行了分析,报告了西部各省域物流业发展现状及其与经济发展关系的现状。通过采用感应力系数和影响力系数,进行了区域物流业及其相关产业与区域经济间的相互影响调查,反映了西部各省区域物流业与经济关联度之间的互动特征及其动态变化趋势,取得西部省域地区物流业与区域经济互动关系并不显著的基本结论,西部各省市区的物流业发展现状与经济发展水平不同,导致两者之间关系在不同省域存在明显的差异;西部区域物流业与区域经济的影响力系数和感应力系数在产业间不同,地区间也存在着差异,应当探索符合区域自身特色的物流业发展战略,促进区域物流业与区域经济的互动平衡发展。     

中外物流业比较及我国的对策

在全面了解国内外物流业发展状况的基础上，提出了我国发展物流业的措施。     

网站管理中若干安全问题的研究

文章从当今主流的加密技术、防火墙管理、常见攻击的类型和预防等方面,寻求解决网站安全度量的行之有效的办法,对近年来因特网用户数呈爆炸性增长,黑客攻击、病毒和信用卡欺诈等安全威胁因为存在更多潜在途径的进入而进一步加剧的情况进行探讨。     

逆杠杆操作嵌入国际供应链——中国加工制造业企业“走出去”参与国际竞争

在跨国公司利用杠杆效应掀起全球化浪潮的同时,也出现了反方向的逆杠杆操作。逆杠杆操作是深度嵌入国际供应链,参与国际竞争的一种重要策略。本文在对实践资料和有限理论研究分析总结的基础上,从理论上对逆杠杆操作的相关问题进行系统地总结论述,以期对理论研究及中国加工制造业企业参与国际竞争有所借鉴。     

LABOR MARKET IMPACTS OF SMOKING REGULATIONS ON THE RESTAURANT INDUSTRY

This paper examines the impact of smoking regulations on restaurant employment in West Virginia, a state with a high rate of smoking prevalence. Using a confidential establishment‐level dataset, our results suggest that smoking bans reduced restaurant employment by between 0.7 and 1.5 workers, depending on model specification. We find that smoking restrictions have heterogeneous impacts across establishments, with the largest impacts on mid‐sized establishments, defined as those with 10–29 employees. Our results also suggest that the impact of smoking restrictions was larger in counties with higher rates of smoking prevalence. (JEL L51, D78, H0)     

Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients

Objective:

This study evaluated differences in medical costs associated with clinical end-points from randomized clinical trials that compared the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, to standard therapy for treatment of patients with venous thromboembolism (VTE).

Research design and methods:

Event rates of efficacy and safety end-points from the clinical trials (RE-COVER, RE-COVER II, EINSTEIN-Pooled, AMPLIFY, Hokusai-VTE trial) were obtained from published literature. Incremental annual medical costs among patients with clinical events from a US payer perspective were obtained from the literature or healthcare claims databases and inflation adjusted to 2013 costs. Differences in total medical costs associated with clinical end-points for the NOACs vs standard therapy were then estimated. One-way and Monte Carlo sensitivity analyses were carried out.

Results:

A lower rate of major bleedings was associated with use of any of the NOACs vs standard therapy. Except for dabigatran, use of NOACs was also associated with a lower rate of recurrent VTE/death. As a result of the reduction in clinical event rates, the overall medical cost differences were ?$146, ?$482, ?$918, and ?$344 for VTE patients treated with dabigatran, rivaroxaban, apixaban, and edoxaban, respectively, vs patients treated with standard therapy.

Conclusions:

When any of the four NOACs are used instead of standard therapy for acute VTE, treatment medical costs are reduced. Apixaban is associated with the greatest reduction in medical costs, which is driven by medical cost reductions associated with both efficacy and safety end-points. Further evaluation may be needed to validate these results in the real-world setting.